Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Kuemmerle, Andrea ^a,b,c   Dodoo, Alex N O ^d   Olsson, Sten ^e   Van Erps, Jan ^f   Burri, Christian ^a,b   Lalvani, Paul S ^g  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d UNIVERSITY OF GHANA   (Ghana)

^e WHO Collaborating Centre for International Drug Monitoring   (Sweden)

^f Roll Back Malaria Department   (Switzerland)

^g RaPID Pharmacovigilance Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; MEFLOQUINE; ARTEMISININ DERIVATIVE;

AFRICA; ARTICLE; CLINICAL EFFECTIVENESS; DATA BASE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; MEDICAL SOCIETY; PUBLIC HEALTH PROBLEM; TREND STUDY; WORLD HEALTH ORGANIZATION; DRUG COMBINATION; HUMAN; MALARIA; METHODOLOGY; STATISTICS; SWEDEN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; SWEDEN;

EID: 79952340261     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-57     Document Type: Article

References (27)

1. WHO, World Malaria Report 2009 Geneva 2009
2. The economic burden of malaria. JL Gallup JD Sachs, Am J Trop Med Hyg 2001 64 1-2 Suppl 85 96 11425181 (Pubitemid 32552575)
3. WHO, Antimalarial Drug Combination Therapy, report of a WHO Technical Consultation Geneva 2001
4. Monitoring and Improving the Flow of ACTs in the Public Sector: Medicines for Malaria Venture; G Jagoe, 2nd Global Health Supply Chain Summit Zaragoza, Spain 2009
5. Focusing on quality patient care in the new global subsidy for malaria medicines. S Moon C Perez Casas JM Kindermans M de Smet T von Schoen-Angerer, PLoS Med 2009 6 1000106 10.1371/journal.pmed.1000106 19621068
6. Affordable Medicines Facility - malaria (AMFm). http://www.theglobalfund. org/en/amfm/?lang=en (accessed on July 16, 2010)
7. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. CJ Whitty C Chandler E Ansah T Leslie SG Staedke, Malar J 2008 7 Suppl 1 7 10.1186/1475-2875-7-S1-S7 19091041
8. Pharmacovigilance of antimalarial treatment in Africa: is it possible? AO Talisuna SG Staedke U D'Alessandro, Malar J 2006 5 50 10.1186/1475-2875-5-50 16780575
9. Beyond registration - measuring the public-health potential of new treatments for malaria in Africa. T Lang D Hughes T Kanyok J Kengeya-Kayondo V Marsh A Haaland M Pirmohamed P Winstanley, Lancet Infect Dis 2006 6 46 52 10.1016/S1473-3099(05)70326-1 16377534 (Pubitemid 41831377)
10. Pharmacovigilance in developing countries. M Pirmohamed KN Atuah AN Dodoo P Winstanley, Bmj 2007 335 462 10.1136/bmj.39323.586123.BE 17823149 (Pubitemid 47401595)
11. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. R Price M van Vugt L Phaipun C Luxemburger J Simpson R McGready F ter Kuile A Kham T Chongsuphajaisiddhi NJ White F Nosten, Am J Trop Med Hyg 1999 60 547 555 10348227 (Pubitemid 29233109)
12. WHO, The importance of pharmacovigilance: safety monitoring of medicinal products Geneva 2002
13. Safety profile of Coartem: the evidence base. C Falade C Manyando, Malar J 2009 8 Suppl 1 6 10.1186/1475-2875-8-S1-S6 19818173
14. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. S Olsson SN Pal A Stergachis M Couper, Drug Saf 2010 33 689 703 10.2165/11536390-000000000-00000 20635827
15. UMC Official member countries and their year of entering the Programme. http://www.who-umc.org/DynPage.aspx?id=13140&mn=1514 (accessed on December 31, 2010)
16. WHO, The Safety of Medicines in Public Health Programmes: Pharmacovigilance an essential tool Geneva 2006
17. The WHO 'Roll Back Malaria Project': planning for adverse event monitoring in Africa. O Simooya, Drug Saf 2005 28 277 286 10.2165/00002018- 200528040-00001 15783238 (Pubitemid 40545764)
18. Steps for completing Global Fund's Round 8 Proposal for Requesting funds for Pharmacovigilance. http://www.rollbackmalaria.org/mmss/docs/ PharmacovigilanceFundingGFround8.pdf (accessed January 10, 2011)
19. Including pharmacovigilance in Global Fund's Round 8 proposal. http://www.rollbackmalaria.org/mmss/docs/PharmacovigilanceIntro-en.pdf (accessed January 10, 2011)
20. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals. A Stergachis RJ Bartlein A Dodoo J Nwokike SP Kachur, Malar J 2010 9 148 10.1186/1475-2875-9-148 20509971
21. World Bank List of Economies of July 2009. http://go.worldbank.org/ K2CKM78CC0 (accessed July 20, 2009)
22. WHO, World Malaria Report 2008 Geneva 2008
23. Round 10 application. http://www.theglobalfund.org (accessed July 16, 2010)
24. PV africa. http://www.pvafrica.org (accessed July 16, 2010)
25. Assessment of Adverse Drug Reaction (ADR) Reporting in Botswana, Ghana, Sierra Leone, Sudan, Zambia, Zimbabwe. P Lalvani S Nag A Aggarwal, 2008 http://www.rapidpharmacovigilance.org 19006430
26. Rapid Pharmacovigilance Implementation in Developing Countries. http://www.rapidpharmacovigilance.org (accessed July 16, 2010)
27. Demographic indicators. http://unstats.un.org/unsd/demographic/products/ socind/default.htm (accessed April 13, 2010)